SCHEMBL1456348

SCHEMBL1456348

CCCC(O)c1cc(-c2c[nH]c3ncccc23)nc(N)n1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDPK1 O15530 11/20 0.66
▸ CDC7 O00311 7/20 0.58
▸ CDK9 P50750 5/20 0.58
▸ CDK5 Q00535 5/20 0.58
▸ MAP4K4 O95819 5/20 0.58
▸ PIM1 P11309 5/20 0.58
▸ PRKACA P17612 5/20 0.58
▸ GSK3B P49841 5/20 0.58
▸ CLK4 Q9HAZ1 5/20 0.58
▸ DYRK1A Q13627 5/20 0.58
▸ DAPK3 O43293 4/20 0.58
▸ CLK2 P49760 4/20 0.58
▸ CDK7 P50613 4/20 0.58
▸ PRKX P51817 4/20 0.58
▸ PRKD3 O94806 3/20 0.58
▸ PAK4 O96013 3/20 0.58
▸ CSNK1A1 P48729 3/20 0.58
▸ MAP4K2 Q12851 3/20 0.58
▸ ROCK1 Q13464 3/20 0.58
▸ CDK8 P49336 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1604217 0.80 PDPK1 (1.00) PDPK1CDC7CDK9CDK5MAP4K4
SCHEMBL1603523 0.78 PDPK1 (1.00) PDPK1CDC7CDK9CDK5MAP4K4
SCHEMBL1604041 0.78 PDPK1 (1.00) PDPK1CDC7CDK9CDK5MAP4K4
SCHEMBL1603903 0.78 PDPK1 (0.60) PDPK1CDC7CDK9CDK5MAP4K4
SCHEMBL1604049 0.77 PDPK1 (1.00) PDPK1CDC7CDK9CDK5MAP4K4
SCHEMBL1603553 0.77 DYRK1A (0.72) PDPK1CDC7CDK9CDK5MAP4K4
SCHEMBL1604071 0.76 PDPK1 (0.78) PDPK1CDC7CDK9CDK5MAP4K4
SCHEMBL1603476 0.75 PDPK1 (0.74) PDPK1CDC7CDK9CDK5MAP4K4
SCHEMBL1603905 0.75 PDPK1 (0.80) PDPK1CDC7CDK9CDK5MAP4K4
SCHEMBL1456993 0.75 PDPK1 (0.63) PDPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420820-B2 Pyrrolopyridinylpyrimidin-2-ylamine derivatives MERCK PATENT GMBH (DE) 2013-04-16 — — US claimed
JP-2011526260-A — — 2011-10-06 — — JP claimed
US-20110218198-A1 Pyrrolopyridinylpyrimidin-2-ylamine derivatives MERCK PATENT GESELLSCHAFT (DE) 2011-09-08 — — US claimed
EP-2291375-A1 PYRROLOPYRIDINYLPYRIMIDIN-2-YLAMINE DERIVATIVES Merck Patent GmbH (DE) 2011-03-09 — — EP claimed
WO-2010000364-A1 PYRROLOPYRIDINYLPYRIMIDIN-2-YLAMINE DERIVATIVES MERCK PATENT GMBH (DE) 2010-01-07 — — WO claimed
US-8420820-B2 Pyrrolopyridinylpyrimidin-2-ylamine derivatives MERCK PATENT GMBH (DE) 2013-04-16 — — US disclosed
US-8420820-B2 Pyrrolopyridinylpyrimidin-2-ylamine derivatives MERCK PATENT GMBH (DE) 2013-04-16 — — US disclosed
US-8420820-B2 Pyrrolopyridinylpyrimidin-2-ylamine derivatives MERCK PATENT GMBH (DE) 2013-04-16 — — US disclosed
US-20110218198-A1 Pyrrolopyridinylpyrimidin-2-ylamine derivatives MERCK PATENT GESELLSCHAFT (DE) 2011-09-08 — — US disclosed
US-20110218198-A1 Pyrrolopyridinylpyrimidin-2-ylamine derivatives MERCK PATENT GESELLSCHAFT (DE) 2011-09-08 — — US disclosed
US-20110218198-A1 Pyrrolopyridinylpyrimidin-2-ylamine derivatives MERCK PATENT GESELLSCHAFT (DE) 2011-09-08 — — US disclosed
EP-2291375-A1 PYRROLOPYRIDINYLPYRIMIDIN-2-YLAMINE DERIVATIVES Merck Patent GmbH (DE) 2011-03-09 — — EP disclosed
WO-2010000364-A1 PYRROLOPYRIDINYLPYRIMIDIN-2-YLAMINE DERIVATIVES MERCK PATENT GMBH (DE) 2010-01-07 — — WO disclosed
WO-2010000364-A1 PYRROLOPYRIDINYLPYRIMIDIN-2-YLAMINE DERIVATIVES MERCK PATENT GMBH (DE) 2010-01-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110218198-A1 Pyrrolopyridinylpyrimidin-2-ylamine derivatives MKI67, CCNT1, CCNI PDPK1 429/4885CDC7 581/4885CDK9 278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback